Bipolar Depression | Treatment Algorithms: Claims Data Analysis | US | 2024

Among bipolar disorder (BPD) patients, depressive episodes are typically more common than manic or mixed episodes; symptoms of bipolar depression include fatigue, insomnia, suicidal ideation, and feelings of worthlessness. The prevalence of bipolar depression among BPD patients, combined with its negative effects, makes the management of depressive episodes a high priority in BPD treatment. Current treatment options are limited; only a few drugs are FDA-approved to treat bipolar depression, and other drugs used for this purpose may have serious side effects, as in the case of lithium and lamotrigine, or limited efficacy. Treatment may be individualized, and psychiatrists usually try different drugs/combinations in nonresponsive patients. Our Treatment Algorithms: Claims Data Analysis provides national patient-level claims data to explore the use of key therapies in both newly diagnosed and recently treated patients, providing insight into the current treatment landscape for bipolar depression.

Questions answered

• What shares do key therapies and brands garner by line of therapy in newly diagnosed bipolar depression patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed bipolar depression patients?
• How have AbbVie’s Vraylar and Intra-Cellular Therapies’ Caplyta been integrated into the treatment algorithm, and what are their sources of business?
• What percentage of bipolar depression patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
• What percentage of bipolar depression patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

Markets covered: United States

Key companies: AbbVie, Intra-Cellular Therapies, Sumitomo Pharma / Sunovion, Teva, Otsuka, Lundbeck, Alkermes, Johnson & Johnson Innovative Medicine

Key drugs: Lithium, lamotrigine, lurasidone, Vraylar, Caplyta, Trintellix, sertraline, quetiapine, olanzapine/fluoxetine

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Key feature

Dashboard featuring interactive visuals, easy navigation, and expanded analyses